Joondalup Health Campus enters an agreement for full commercial rollout of HeraCARE

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02477699-6A1073157?access_token=83ff96335c2d45a094df02a206a39ff4

• Joondalup Health Campus (JHC) has entered into a full-scale long-term commercial agreement with medical data and technology company HeraMED (ASX:HMD) to adopt the complete HeraCARE solution as the primary standard of care offered for their audience of expecting mothers
• Commercial terms reached under the paid pilot agreement, including the SaaS fees, will extend for 12 months, with both parties exploring extension of the contract for a further three years
• The contract value for the first 12 months is expected to be approximately A$220,000
• HMD will progressively deliver HeraCARE SaaS licences (including the HeraBEAT smart foetal monitors) to support JHC’s services expansion
• This is the first major Healthcare group to adopt the comprehensive HeraCARE virtual and remote monitoring solution as part of their innovative care model for pregnant mothers
• This agreement validates HeraMED’s commercialisation strategy undertaking clinical trials leading to paid pilots and then ultimately full commercial deployment within a leading hospital group
• JHC (part of Ramsay Health Care) is one of Western Australia’s largest hospitals, a leading medical institution, and a maternity care service provider to an average of 3,000 expectant mothers annually

HeraMED Limited (ASX:HMD), a leader in the digital transformation of maternity care, is delighted to announce it has entered into a commercial agreement with Joondalup Health Campus (JHC) for JHC to offer the HeraCARE solution as the primary standard of care for their entire audience of expecting mothers. This is a major milestone for HeraMED, as it is the first full-scale commercial roll-out of the technology as a standard service to be offered to all suitable pregnant mothers by a hospital.

HeraMED CEO and Cofounder Mr. David Groberman said: “This is a truly significant milestone for HeraMED. I am delighted we have reached this agreement with JHC as it demonstrates that our strategy of delivering clinical validation of the HeraCARE platform, which led to a successful paid pilot, provided the correct foundation for broader commercial rollout of HeraCARE within the hospital. 2022 will be a transformative year for HeraMED as we work towards delivering similar deployments with other key partners....

This notice brings HMD out of is suspension and trading halt

Hopefully this is the first of many to come

Disc:I hold

Edit~ Spelling

Medical technology company, HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”) requests that the securities of the Company be placed into a trading halt of up to two trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

1. The trading halt is requested pending an announcement by the Company regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.
2. The Company requests that the trading halt remains in place until the earlier of the Company releasing an announcement regarding the commercial agreement or prior to the commencement of trading on Thursday, 20 January 2022.
3. The Company is not aware of any reason why the request for the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Your faithfully

Jonathan Hart Company Secretary

As with all companies like this, it takes time to get up and running, hopefully this is the start of the good news.

Disc: I hold

PS I highlighted point no1